<DOC>
	<DOCNO>NCT01261247</DOCNO>
	<brief_summary>Panobinostat may stop growth cancer cell block enzymes need cell growth . This phase II trial study well panobinostat work treat patient relapsed refractory non-Hodgkin lymphoma</brief_summary>
	<brief_title>Panobinostat Treating Patients With Relapsed Refractory Non-Hodgkin Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To evaluate proportion confirm response LBH589 patient relapse refractory non-Hodgkin lymphoma . SECONDARY OBJECTIVES : I . To describe toxicity associate LBH589 patient NHL . II . To evaluate overall survival , progression-free survival , duration response patient treat LBH589 . TERTIARY OBJECTIVES : I . To evaluate pharmacokinetics LBH589 . II . To assess correlation clinical ( toxicity and/or tumor response activity ) effect pharmacologic ( pharmacokinetic/pharmacodynamic ) parameter , and/or biologic ( correlative laboratory ) result . OUTLINE : Patients receive oral panobinostat 3 time weekly . Treatment repeat every 28 day 12 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 6 month 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<criteria>Inclusion Criteria Biopsyproven relapse refractory nonHodgkin lymphoma require treatment , fail , unable tolerate , refuse available active therapy ; patient treatment option consider curative ( NOTE : patient lymphoma without CNS involvement , rebiopsy necessary unless patient previous biopsy = &lt; 6 month prior treatment protocol intervene treatment ; patient biopsyproven CNS lymphoma time require rebiopsy eligible study ) ; NOTE : relapse NHL define NHL relapse least one prior therapy available curative therapy ; refractory NHL define NHL progress respond recent therapy least one prior therapy available curative therapy Measurable disease CT MRI CT portion PET/CT : must least one lesion single diameter &gt; = 2 cm tumor cell blood &gt; = 5 x 10^9/L ; skin lesion use area &gt; = 2 cm least one diameter photograph ruler The following disease type eligible : transform lymphoma : diffuse large B cell lymphoma , mantle cell lymphoma , follicular lymphoma grade III ; precursor B lymphoblastic leukemia/lymphoma ; mediastinal ( thymic ) large Bcell lymphoma ; Burkitt lymphoma/leukemia ; precursor Tlymphoblastic leukemia/lymphoma ; primary cutaneous anaplastic large cell lymphoma ; anaplastic large cell lymphoma primary systemic type ; small lymphocytic lymphoma/chronic lymphocytic leukemia ; follicular lymphoma , grade 1 , 2 ; extranodal marginal zone Bcell lymphoma MALT type ; nodal marginal zone Bcell lymphoma ; splenic marginal zone Bcell lymphoma ; peripheral T cell lymphoma , unspecified ; anaplastic large cell lymphoma ( T null cell type ) ; lymphoplasmacytic lymphoma ( Waldenstrom Macroglobulinemia ) ; CNS lymphoma ; post transplant lymphoproliferative disorder ; mycosis fungoides/Sezary syndrome ; primary effusion lymphoma ; blastic NKcell lymphoma ; adult Tcell leukemia/lymphoma ; extranodal NK/Tcell lymphoma , nasal type ; enteropathytype Tcell lymphoma ; hepatosplenic Tcell lymphoma ; subcutaneous panniculitislike Tcell lymphoma ; angioimmunoblastic Tcell lymphoma ; anaplastic large cell lymphoma primary cutaneous type For lymphoplasmacytic lymphoma patient without measurable lymphadenopathy , measurable disease define follow criterion : bone marrow lymphoplasmacytosis &gt; 10 % lymphoplasmacytic cell aggregate , sheet , lymphocyte , plasma cell , lymphoplasmacytic cell bone marrow biopsy quantitative IgM monoclonal protein &gt; 1,000 mg/dL ANC &gt; = 1000/uL Hgb &gt; = 9 g/dl PLT &gt; = 75,000/uL Total bilirubin = &lt; 1.5 x upper limit normal ( ULN ) total bilirubin &gt; 1.5 x ULN direct bilirubin must normal AST = &lt; 3 x ULN Albumin &gt; 3.0 g/dl Creatinine = &lt; 2.5 x ULN Serum potassium , magnesium phosphorus &gt; = LLN = &lt; 1.2 x ULN Total serum calcium [ correct serum albumin ] ionize calcium &gt; = LLN Clinically euthyroid ; patient permit receive thyroid hormone supplement treat underlying hypothyroidism Baseline MUGA ECHO must demonstrate LVEF &gt; = low limit institutional normal Ability understand willingness sign write informed consent document Willingness return Mayo Clinic Life expectancy &gt; = 12 week Willingness provide blood tissue sample research study require protocol Negative pregnancy test do = &lt; 7 day prior registration , woman childbearing potential ECOG performance status ( PS ) 0 , 1 2 Exclusion Criteria Prior HDAC , DAC , HSP90 inhibitor valproic acid treatment cancer Patients need valproic acid medical condition study within 5 day prior first panobinostat treatment Candidate know standard therapy patient 's disease potentially curative Uncontrolled infection require ongoing antibiotic Any prior therapy lymphoma within previous 2 week standard treatment within 4 week experimental therapy unless patient recover nadir previous treatment level meet inclusion criterion Receiving corticosteroid &gt; 20mg prednisone per day ( equivalent ) Persistent toxicity &gt; = grade 2 prior chemotherapy biological therapy regardless interval since last treatment Patients congenital long QT syndrome History presence sustain ventricular tachyarrhythmia ( patient history atrial arrhythmia eligible discuss study PI prior enrollment ) Any history ventricular fibrillation torsade de pointes Bradycardia define HR &lt; 50 bpm ; patient pacemaker eligible HR &gt; = 50 bpm Screening ECG QTcFredericia ( QTcF ) &gt; 450 msec Right bundle branch block + leave anterior hemiblock ( bifascicular block ) Patients myocardial infarction unstable angina = &lt; 6 month prior registration Other clinically significant heart disease ( e.g . CHF NY Heart Association class III IV , uncontrolled hypertension , history labile hypertension , history poor compliance antihypertensive regimen ) Pregnant woman woman reproductive ability unwilling use effective contraception study 3 month stop treatment Nursing woman Men unwilling use condom ( even undergone prior vasectomy ) intercourse woman , take drug 3 month stop treatment Other concurrent chemotherapy , immunotherapy , radiotherapy , ancillary therapy consider investigational ( utilized nonFDAapproved indication context research investigation ) ; patient recover immunotherapy , chemotherapy , radiation therapy related toxicity Known positivity human immunodeficiency virus ( HIV ) hepatitis C uncontrolled disease ; baseline test HIV hepatitis C require Active malignancy require treatment would interfere assessment response lymphoma protocol treatment Inability swallow impairment gastrointestinal function gastrointestinal disease may significantly alter absorption drug ( e.g . ulcerative disease , uncontrolled nausea , vomit , diarrhea &gt; CTCAE Grade 2 , malabsorption syndrome small bowel resection ) would preclude use oral medication Thrombolic embolic event cerebrovascular accident include transient ischemic attack within past 6 month Any severe and/or uncontrolled medical condition condition , treat physician 's opinion , could adversely impact ability participate study ; patient chronic oxygen therapy , liver disease cirrhosis , chronic hepatitis chronic persistent hepatitis , uncontrolled infection exclude Concomitant use strong moderate CYP3A4 inhibitor Using medication relative risk prolong QT interval induce torsade de pointes treatment discontinue switched different medication prior start study drug Active bleeding tendency . NOTE : Patients therapeutic anticoagulation monitor carefully maintain therapeutic level anticoagulation avoid increase risk bleeding due concurrent drug induce thrombocytopenia . It suggest patient require anticoagulation therapy therapy use low molecular weight heparin ( LMWH ) . Major surgery = &lt; 4 week prior registration recover side effect therapy History prior malignancy except properly treat basal cell squamous cell carcinoma skin , situ cervical cancer , situ breast cancer early stage prostate cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>